Aiming to facilitate treatment targeting RET fusions, we analyzed the molecular portfolio of 1,652 patients with lung cancer who underwent targeted NGS, and revealed the genetic and clinical prognostic characteristics of female patients with lung cancer harboring RET fusion for the first time. The gene discussed is RET; the disease is lung carcinoma.